ArticleAntimicrobial agents and chemotherapy2017
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.Journal of clinical pharmacology · 2018Trial
- What's in a Name? Etymology and History of Antibacterials and Antifungals.Open forum infectious diseases · 2026Review
- Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
- Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps.Mycopathologia · 2024Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- A Mini-Review of In Vitro Data forJournal of fungi (Basel, Switzerland) · 2024Review
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
- Engineered and total biosynthesis of fungal specialized metabolites.Nature reviews. Chemistry · 2024Review
- Novel Antifungals andJournal of fungi (Basel, Switzerland) · 2023Article
- Antifungal resistance, combinations and pipeline: oh my!Drugs in context · 2023Review
- Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.Infection and drug resistance · 2023Review
- Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2022Review
- Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.Expert opinion on investigational drugs · 2022Article
- Emerging and future strategies in the management of recalcitrant Candida auris.Medical mycology · 2022Review
- Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.Drugs in R&D · 2022Review
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SCY-078 (MK-3118) is a novel, semisynthetic derivative of enfumafungin and represents the first compound of the triterpene class of antifungals. SCY-078 exhibits potent inhibition of β-(1,3)-d-glucan synthesis, an essential cell wall component of many pathogenic fungi, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.